Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen s Q1 Revenues Slide 1 Percent as Earnings Grow ...

NEW YORK, May 3 (GenomeWeb News) - Qiagen yesterday reported a slight dip in revenues and increased earnings for the first quarter of 2005.


Revenues for the quarter were inched down to $95 million from $96.1 million during the same period in 2004. Some of this decrease was related to the sale of Qiagen's synthetic DNA business unit in the second quarter of last year, which contributed $10.4 million in revenues during the first quarter of 2004.


Research and development costs were slightly up this quarter, at $10.1 million from $9.4 million during the year-ago period.


Qiagen's net income totaled $13.9 million, or $.09 per share, during the quarter, up from $11.4 million, or $.08 per share, in last year's quarter.


As of March 31, Qiagen had $210.3 million in cash and cash equivalents, and $34.7 million in marketable securities.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.